Lactobacillus plantarum – LP02 (LMG P-21020)

Tabella dei contenuti

Clinical indications

antipathogenic activity, Cystitis, immune stimulation, rebalance of intestinal microbiota, vaginal candidiasis

Area of use

Gastroenterology strain | Antipathogenic activity

Characteristics

FUNCTIONALITY
Inhibition of E. coli

Scientific support

In vitro studies
Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32.


Immunology blend | Immune stimulation

  • Lactobacillus rhamnosus – LR04 (DSM 16605)
  • Lactobacillus rhamnosus – LR05 (DSM 19739)
  • Lactobacillus plantarum – LP01 (LMG P-21021)
  • Lactobacillus plantarum – LP02 (LMG P-21020)
  • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 2.5 billion CFU + 5 billion CFU + FOS or GOS


FUNCTIONALITY
Reinforcement of the natural defences • Reduction of the intestinal discomfort • Rebalance of the intestinal microbiota

Scientific support

Human clinical trial
1) Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroenterology, 2008; 42(2): 224-233.
2) Belcaro G. et al. Prevention of flu episodes with colostrum and Bifivir compared with vaccination: an epidemiological, registry study. Panminerva Medica 2010;52:269-75.

In vitro study
Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Gastroenterol. 2018;52:S57-S61.

+ Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains


Immunology blend | Immune stimulation

  • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
  • Lactobacillus rhamnosus – LR04 (DSM 16605)
  • Lactobacillus plantarum – LP02 (LMG P-21020)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
10 billion CFU + 10 billion CFU + 10 billion CFU + 3g


FUNCTIONALITY
Reinforcement of the natural defences • Reduction of the incidence, severity and duration of Acute Respiratory Infections (ARI) during the cold season

Scientific support

Human clinical trial
Pregliasco F. et al. A New Chance of Preventing Winter Diseases by the Administration of Symbiotic Formulations. Journal of Clinical Gastroente- rology, 2008; 42(2): 224-233.

In vitro study
Mogna L. et al. Micronized Cells of the Probiotic Strain Bifidobacterium lactis BS01 Activate Monocyte Polarization: A New Approach. J Clin Ga- stroenterol. 2018;52:S57-S61.

+ Internal data on immune stimulation and anti-pathogen activity available upon request for certain strains


Gynecology blend | Vaginal candidiasis – Bacterial vaginosis

  • Lactobacillus plantarum – LP02 (LLMG P-21020)
  • Lactobacillus fermentum – LF10 (DSM 19187)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
500 million per strain


FUNCTIONALITY
Vaginal health • Counteraction of Candida vulvovaginitis • Counteraction of Candida vulvovaginitis including recurrence

Scientific support

Clinical study
Murina F. et al. Thymol, eugenol and lactobacilli in a medical device for the treatment of bacterial vaginosis and vulvovaginal candidiasis. New Microbiologica, 41,3, 220-224, 2018, ISN 1121-7138.


Urology strain | Antipathogenic activity

Characteristics

FUNCTIONALITY
Cystitis • Inhibition of E. coli

Scientific support

In vitro studies
Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.

+ Internal data on anti-inflammatory and anti-oxidant properties available upon request for some of these strains